A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers

Phase 1

Suspended

• Conditions: Parainfluenza; Respiratory Viral Infections
• Interventions: Biological: Sendai virus vaccine

• Registration Number: NCT00186927
• Lead Sponsor: St. Jude Children's Research Hospital

Brief Summary

Croup is an illness of young children that is caused by a virus. With this illness, the child has fever, cough, and hoarseness. Although the illness usually gets better in 2 to 4 days, some children may be admitted to the hospital and a few infants may require an intervention to help their breathing. This illness is most often caused by a virus called parainfluenza virus type 1, but it can be caused by other viruses. The experimental vaccine that is being investigated in this study is intended to try to prevent croup caused by parainfluenza virus type 1. Currently, there are no vaccines to prevent this virus, or medications available to treat the illness once infection has occurred.

This research study is testing a new experimental live-virus vaccine that is given by placing liquid drops in the nose. The Sendai virus is very similar to the virus that causes croup, but it has never been found to cause illness in people. Previous studies in animals have shown that the vaccine provided protection against the croup virus, and did not cause illness. Many people have been exposed to the Sendai virus, but no one has been known to develop illness. Several healthy adults have been given the Sendai virus vaccine being studied, and they did not experience any serious side effects or illness.

Detailed Description

The main aim of the study is to assess the tolerance and safety of escalating doses of intranasal Sendai virus in children and toddlers.

The secondary objective of the study is to assess the magnitude and duration of the immune response elicited by intranasal Sendai virus. Responses between seropositive and seronegative children will be compared.

This study also tests the safety and immunogenicity of a booster vaccination at the highest dose tolerated during primary immunization dose-escalation.

Study Timeline

• Study Start: 2005-05-05
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-16
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-12
• Last Update Posted: 2024-02-13
• Primary Completion: 2025-01
• Study Completion: 2026-01

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

• History of allergy to eggs or gentamicin
• History of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition
• Children who have a family history of primary immunodeficiency or lack history of maternal or paternal immune status
• Height or weight less than 5th percentile
• Upper respiratory tract infection (URI) or household member with URI
• Evidence of developmental delay or evolving neurological disorders
• Household member or daycare contact (i.e. stay in the same room in daycare) less than 24 months of age if same room contact is expected within 14 days of vaccination or 7 days after booster, or prior to evidence of vaccine clearance
• Immunodeficient household members or other close contacts if same room contact is expected within 14 days of vaccination or 7 days after booster, or prior to evidence of vaccine clearance
• Current use of investigational or immunosuppressive drugs (e.g., steroids)
• Current use of antibiotics or antivirals

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Participants	Sendai virus vaccine	Participants will be studied in three cohorts: * Healthy seropositive children 3 years up to 6 years * Healthy seropositive toddlers 12 months up to 24 months * Healthy seronegative toddlers 12 months up to 24 months. Each cohort will receive Sendai virus vaccine.

Primary Outcome Measures

Name	Time	Method
To determine if giving live Sendai virus (in the form of a vaccine) to children through their nose is safe (causes no serious illness)	6 months after enrollment complete
To determine if a child's body responds to the presence of the Sendai virus by making proteins in the blood called antibodies that can find and kill the croup virus	6 months after enrollment complete

Trial Locations

Locations (1)

St. Jude Children's Research Hospital; 🇺🇸 Memphis, Tennessee, United States